Is this finally the year CRISPR Therapeutics (NASDAQ: CRSP) bounces back? The biotech has lagged the market in recent years, but shares are up 50% over the past three months and have climbed 42% since ...

Challenges persist despite promising advance In January 2025, the National Institute for Health and Care Excellence (NICE) approved the use of the gene editing therapy exagamglogene autotemcel ...

ZUG, Switzerland and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Speaking at a review meeting held at the Directorate of Health Services in Mumbai, Abitkar said that inclusion in the ...

If successful, the access model for sickle cell disease gene therapies could serve as a blueprint for other such treatments ...

Kendrapada: Odisha has emerged as the state with the highest number of sickle cell patients in India, with a staggering 96,080 cases registered on the.

New tools and delivery vehicles for CRISPR are only truly beneficial if we can simultaneously improve the affordability and access.

VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and ...

Lorna Newbrook is aiming for 1,000 blood donations in memory of her husband Mike, raising awareness of the life-saving power of blood.

Craig Melvin, a long-time blood donor, is rolling up his sleeve on live TV for a good cause. The TODAY show co-anchor knows ...

CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.